Alphatec Holdings reported a 1.6 percent decrease in third quarter revenue for Alphatec Spine. The company reported $46.8 million, compared with $47.6 million over the same period last year. Net revenues were also down $1.7 million in the third quarter of 2012, driven by the company's biologics process.
International sales reached $15.9 million, $1 million more than the same period last year. As part of a January 2012 settlement, the company agreed to pay $18 million to Cross Medical for a license agreement dispute, with $1 million paid during the third quarter.
The company recently launched a new spinous process fixation system, BridgePoint, and a new synthetic bone growth biologic, Alphatec NEXoss.
More Articles on Orthopedic Devices:
Globus Medical 3Q Worldwide Sales Reach $94.8M, Up 12.5%
X-spine Announces FDA Approval for 2 Spine Systems
Zimmer Pulls Metal-on-Metal Hip Device From Australia
International sales reached $15.9 million, $1 million more than the same period last year. As part of a January 2012 settlement, the company agreed to pay $18 million to Cross Medical for a license agreement dispute, with $1 million paid during the third quarter.
The company recently launched a new spinous process fixation system, BridgePoint, and a new synthetic bone growth biologic, Alphatec NEXoss.
More Articles on Orthopedic Devices:
Globus Medical 3Q Worldwide Sales Reach $94.8M, Up 12.5%
X-spine Announces FDA Approval for 2 Spine Systems
Zimmer Pulls Metal-on-Metal Hip Device From Australia